Investing

We offer our investors exposure to premium biotech and pharmaceutical manufacturing properties, employing tax-advantaged strategies like cost segregation, cash-out refinancing, and 1031 exchanges to optimize shareholder value.

Our primary focus is acquiring high-quality off-market GMP facilities through sale-leaseback arrangements with established commercial tenants. Deal sizes typically range from $5M to $30M, spanning major research and innovation hubs across the United States.

Our aim is to provide investors with returns exceeding 20% annually over a 4 to 5-year period.